India’s biggest pharmaceutical company, with a market capitalization of $43 billion, has held preliminary discussions with global lenders to arrange financing for a possible deal, the people said, asking not to be identified because the information is private.
Considerations are preliminary and Sun Pharma may decide to not pursue a bid, the people said. There could also be other suitors for Organon, they said.
The
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
